ERBB2 and breast cancer: Combined with the data that PI3K-inhibitors can sensitize HER2-positive breast cancer cells to hypoxic stress and that overexpression of HER2 leads to overexpression of AKT2, a HER2-mediated pro-survival signaling via AKT2 is suggestable [203].